<DOC>
	<DOCNO>NCT00328237</DOCNO>
	<brief_summary>The purpose study evaluate incidence neutrophil engraftment transplantation one two cord blood unit meet predetermined total minimum cell dose 2.0 x 10 seventh total nucleate cell ( TNC ) /kg .</brief_summary>
	<brief_title>Treatment Hematologic Malignancies With Single-Unit Double-Unit Cord Blood Transplantation</brief_title>
	<detailed_description>This non-randomized , phase II protocol evaluate engraftment cord blood treatment myeloablative conditioning fludarabine , total body irradiation cyclophosphamide . All patient receive tacrolimus mycophenolate mofetil prophylaxis graft-vs-host disease . Conditioning Regimen : - Days -10 -7 : Fludarabine 30mg/m2/day IV - Days -7 -4 : TBI 165 centigray BID - Days -3 -2 : Cyclophosphamide 40mg/kg/day IV Day 0 : Infusion Cord Blood Cells Graft-vs-Host Disease Prophylaxis - Day -1 : Start tacrolimus 0.03mg/kg/day IV - Day 0 : Start MMF 7.5mg/kg IV BID</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Patients must : Be age 18 49 year inclusive . Have histologically prove hematologic malignancy must meet accepted indication allogeneic stem cell transplantation : Acute myeloid leukemia ( AML ) : highrisk first complete remission ( CR ) , near first CR ( &lt; 20 % marrow blast induction therapy ) , beyond first remission . Acute lymphoblastic leukemia highrisk feature first remission ( Philadelphia chromosome positive similar highrisk feature ) , near first CR ( &lt; 20 % marrow blast induction therapy ) , beyond first remission . Chronic myeloid leukemia : chronic phase ( CP ) fail Gleevec intolerant sign fail treatment , history accelerate blast phase . Storage autologous peripheral blood stem cell recommend group patient , particularly chronic phase . NonHodgkin â€™ lymphoma : aggressive histology relapse primary refractory disease eligible autologous transplantation . Patients lowgrade histology must either fail 2 line systemic chemotherapy include one rituximabbased regimen . Radioimmunotherapy consider equivalent one line chemotherapy . Excluded prior radiotherapy chest prior autologous transplantation . Myelodysplastic syndromes International Prognostic Scoring System ( IPSS ) score 1.5 great . Other hematological malignancy approve pipeline meeting case case basis . Must also approve principal investigator . Have HLAmatched 1antigen mismatch related donor HLAmatched unrelated stem cell donor , delay involve perform search likely detrimental patient . Have ECOG performance status 0 1 time transplant . Have major end organ ( heart , lung , liver , kidney ) assess deem adequate withstand effect highdose therapy plan protocol . Have give voluntary informed consent . Patients ineligible protocol : Have comorbid medical condition , psychiatric condition , organ dysfunction make highrisk treatment failure , fail medical compliance , regimenrelated toxicity highdose therapy . Patients follow exclude : Pulmonary : hemoglobin ( Hb ) adjust diffuse capacity lung carbon monoxide ( DLCO ) &lt; 60 % , forced expiratory volume 1 second ( FEV1 ) &lt; 70 % predict , receive continuous supplemental oxygen ; Cardiac : leave ventricular ejection fraction ( LVEF ) &lt; 50 % treatment congestive heart failure ; Renal : serum creatinine great 2.0 calculated creatinine clearance &lt; 50 cc/min ; Liver : ALT , AST , serum bilirubin &gt; 1.5 x upper limit normal ( ULN ) . Any patient elevate transaminase careful evaluation cause liver biopsy may require principle investigator . An elevated alkaline phosphatase fractionate , liver origin , evaluate transaminase . Are female pregnant , lactating , positive pregnancy test . Have history previous malignancy except nonmelanoma skin cancer insitu carcinoma cervix , unless patient progressionfree &gt; 5 year Are HIV positive Refractory malignancy : acute leukemia great 30 % blast bone marrow unless untreated first relapse AML untreated myelodysplastic syndrome evolve AML . Acute leukemia great 1000 blasts/ul peripheral blood . Uncontrolled central nervous system ( CNS ) leukemia lymphoma . Prior autologous allogeneic transplantation use myeloablative regimen . Uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 140 , diastolic blood pressure [ DBP ] &gt; 90 ) hypertension require &gt; 2 drug good control ( SBP &lt; 130 , DBP &lt; 90 ) . Invasive mold infection uncontrolled receive less one month antifungal therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>Cord Blood Transplant</keyword>
	<keyword>Umbilical cord blood transplant</keyword>
	<keyword>Transplant</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Total Body Irradiation</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>